Parkinson’s UK & King’s College London Plan Pioneering Clinical Trial to Treat Psychosis in Parkinson’s Patients Using Cannabidiol

Parkinson’s UK & King’s College London Plan Pioneering Clinical Trial to Treat Psychosis in Parkinson’s Patients Using Cannabidiol

Oct 14, 2019 | CNS, Hallucinations, Kings College London, Parkinson's Disease, Parkinson's UK, Psychosis

Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, has partnered with investigators at King’s College London to invest £1.2 million in a pioneering Phase II clinical trial investigating the use of cannabidiol (CBD)—a compound found...
Kings College London: A Novel Gene Therapy Addressing Recessive Dystrophic Epidermolysis Bullosa (RDEB) Shows Promise

Kings College London: A Novel Gene Therapy Addressing Recessive Dystrophic Epidermolysis Bullosa (RDEB) Shows Promise

Jul 27, 2019 | Gene-Modified Autologous Fibroblasts, Kings College London, Recessive Dystrophic Epidermolysis Bullosa, Stem Cell

King’s College London, in collaboration with University College, London conducted a Phase I clinical trials focused on recessive dystrophic epidermolysis bullosa (RDEB), a severe form of blistering skin disease caused by mutations in COL7A1 gene. The UK-based study...

Pin It on Pinterest